KYORIN PharmaceuticalKYORIN Pharmaceutical Co., Ltd.4569東証プライム医薬品FY ending Mar 2026, consolidated, J-GAAP

KYORIN Pharmaceutical FY ending Mar 2021 results

KYORIN Pharmaceutical brought in ¥102.9B in revenue.

Out of every ¥100 of sales, about ¥6 is left as operating profit.

Revenue changed -6.4% from the prior year, operating profit -22.9%.

Revenue and profit pattern

Revenue and profit down

Revenue -6.4% · profit -22.9%, calculated from disclosed figures.

Operating leverage: 3.56× (profit growth ÷ revenue growth)

FY ending Mar 2020 → FY ending Mar 2021

FY ending Mar 2020 → FY ending Mar 2021

For every ¥100 KYORIN Pharmaceutical sells, how much goes where, and how much is kept.

FY ending Mar 2021

Gross margin50.2%

Operating margin5.6%

Net margin6.0%

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Show source documents (5)

EDINET (FSA Japan)
有価証券報告書－第67期(2024/04/01－2025/03/31)
ID S100W05E2025-06-19Open
EDINET (FSA Japan)
有価証券報告書－第66期(2023/04/01－2024/03/31)
ID S100TQ0U2024-06-24Open
EDINET (FSA Japan)
有価証券報告書－第65期(2022/04/01－2023/03/31)
ID S100R2IL2023-06-26Open
EDINET (FSA Japan)
有価証券報告書－第64期(令和3年4月1日－令和4年3月31日)
ID S100OCVJ2022-06-24Open
EDINET (FSA Japan)
有価証券報告書－第63期(令和2年4月1日－令和3年3月31日)
ID S100LKCY2021-06-21Open

Extracted from XBRL: 51 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.